Reuters |
FDA staff finds no new safety problems with Glaxo's asthma drug
Reuters (Reuters) – GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two … Ad Comm meeting approaches for expanded indication for Glaxo's COPD med … |
View full post on asthma – Google News